Phase 2 N=20 Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: 2-month Progression-Free Survival Rate — 10; 10 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants
Body Temperature
Primary: Mean Axillary Admission Temperature — 36.77; 36.68 Degrees Celsius — p=0.7294
Phase 4 N=640 Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical
Osteoarthritis
Primary: Total Blood Loss — 323.59; 271.22 ml
N/A N=45 Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation
Stress Related Disorder · Anxiety
Primary: Galvanic Skin Response (GSR) — .45; .56; .65; .23 micro-Siemens
Phase 2 N=58 Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Serum MMP7 Level — -0.15; 0.88 ng/ml — p=0.2072
Phase 2 N=6 Oral OKT3 for the Treatment of Active Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=180 Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
Chronic Liver Disease · Non-Alcoholic Fatty Liver Disease · Hepatitis C Virus (HCV) Coinfection
Primary: Liver Elasticity Value Measured Using Sonoelastography (SE) — 7.225; 7.332; 8.548; 12.101 kilopascals (kPa)
Phase 2 N=59 Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery
Pain, Post-operative
Primary: Number of Subjects With Adverse Events — 12; 10; 10 Participants
Phase 3 N=549 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Medulloblastoma
Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS
Phase 2 N=9 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Myelodysplastic Syndrome
Primary: The Number of Patients Who Achieved a Clinical Response — 5 Participants
Phase 2 N=65 Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Glioblastoma
Primary: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1] — 6; 1; 7; 1 Participants
Phase 2 N=22 A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
Medulloblastoma
Primary: Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date…
Phase 3 N=61 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 7.77; 7.84 units on a scale — p=.267
N/A N=52 Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
Benign Uterine Disease
Primary: The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side…
Phase 4 N=207 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder With Hyperactivity
Primary: ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale) — -7.77; -7.99; -10.66; -4.14 units on a scale — p=<.01